TherapeuticsMD (TXMD) Projected to Post Earnings on Tuesday

TherapeuticsMD (NASDAQ:TXMD) is expected to post its Q3 2026 resultson Tuesday, November 17th. Analysts expect TherapeuticsMD to announce earnings of ($6.1250) per share and revenue of $19.77 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Tuesday, August 11th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($6.12) by $6.13. The company had revenue of $0.87 million for the quarter, compared to analyst estimates of $19.77 million. TherapeuticsMD had a negative return on equity of 1.09% and a negative net margin of 6.64%.

TherapeuticsMD Stock Down 2.9%

Shares of TXMD stock opened at $1.69 on Tuesday. The stock has a market cap of $19.55 million, a price-to-earnings ratio of 84.50 and a beta of 0.68. The business’s fifty day moving average is $2.00 and its 200 day moving average is $2.10. TherapeuticsMD has a twelve month low of $1.29 and a twelve month high of $2.95.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered TherapeuticsMD from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, TherapeuticsMD presently has a consensus rating of “Sell”.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc was a pharmaceutical company focused on developing and commercializing products for women’s health. Its portfolio addressed contraception, menopause-related conditions, pregnancy-related nausea, and nutritional support, with products marketed primarily in the United States.

The company’s principal products included ANNOVERA, a reusable, year-long vaginal contraceptive system; IMVEXXY, vaginal inserts containing estradiol for the treatment of moderate to severe vaginal symptoms associated with menopause; and BIJUVA, an oral hormone therapy combining estradiol and progesterone.